COVID-19 pill Paxlovid moves closer to full U.S. FDA approval
Pfizer's COVID-19 pill Paxlovid won another vote of confidence from U.S. health advisers Thursday, clearing the way for its full regulatory approval by the Food and Drug Administration.
The medication has been used by millions of Americans since the FDA granted it emergency use authorization in late 2021. The agency has the final say on giving Pfizer's drug full approval and is expected to decide by May.
A panel of outside experts voted 16-1 that Paxlovid remains a safe and effective treatment for high-risk adults with COVID-19 who are more likely to face hospitalization and death due to the virus.
"We still have many groups that stand to benefit from Paxlovid, including unvaccinated persons, under-vaccinated persons, the elderly and the immuno-compromised," said Dr. Richard Murphy of the Department of Veterans Affairs.
The FDA said using Paxlovid in high-risk patients could prevent 1,500 COVID-19 deaths and 13,000 hospitalizations per week.
The panel's positive vote was widely expected, given that Paxlovid has been the go-to treatment against COVID-19, especially since an entire group of antibody drugs has been sidelined as the virus mutated.
The U.S. continues reporting about 4,000 deaths and 35,000 hospitalizations weekly, the FDA noted.
The agency asked its panel of independent medical experts to address several lingering questions involving Paxlovid, including which people currently benefit from treatment and whether the drug plays a role in cases of COVID-19 rebound.
The panel agreed with assessments by both the FDA and Pfizer that found no clear link between the use of Paxlovid and returning symptoms, but said more information is needed from studies and medical records data. High-profile cases drew attention to the issue last year, including President Joe Biden and first lady Jill Biden.
Between 10 per cent and 16 per cent of patients across multiple Pfizer studies had symptoms return, regardless of whether they'd received Paxlovid or a dummy pill. Such cases "likely reflect natural COVID-19 progression," the FDA concluded.
The federal government has purchased more than 20 million doses of Paxlovid and encouraged health professionals to prescribe it aggressively to help prevent severe COVID-19. But that's led to concerns of overprescribing and questions of whether some patients are needlessly getting the drug.
Pfizer originally studied Paxlovid in the highest-risk COVID-19 patients: unvaccinated adults with other health problems and no evidence of prior coronavirus infection. But that doesn't reflect the U.S. population today, where an estimated 95 per cent of people have protection from at least one vaccine dose, a prior infection or both.
The FDA reviewed Pfizer data showing Paxlovid made no meaningful difference in otherwise healthy adults, whether or not they'd been previously vaccinated.
But when FDA teased out data for high-risk adults -- regardless of their vaccination or infection history -- Paxlovid still showed a significant benefit, reducing the chance of hospitalization or death between 60 per cent and 85 per cent, depending on individual circumstances. Patients in that group included seniors and those with serious health problems, such as diabetes, obesity, lung disease and immune-system disorders.
With so many different factors, panellists said prescribing Paxlovid will remain a case-by-case decision.
Dr. Sankar Swaminathan of the University of Utah and other panellists stressed the importance of managing potentially dangerous drug interactions between Paxlovid and other commonly used medications.
------
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Science and Educational Media Group. The AP is solely responsible for all content.
COVID-19 COVERAGE
CTVNews.ca Top Stories
BREAKING | Danielle Smith's UCP holds onto power in Alberta
Danielle Smith is still the premier of Alberta, surviving a vigorous campaign and a tight vote Monday against NDP challenger Rachel Notley.

Singh calls for foreign interference rapporteur Johnston to step aside
NDP Leader Jagmeet Singh is pushing for special rapporteur David Johnston to 'step aside' from his role examining the issue of foreign interference before he embarks on public hearings.
New Democrat MP says she is target of foreign interference by China
New Democrat MP Jenny Kwan said Monday that Canada's spy agency has confirmed her long-held belief she is being targeted by the Chinese government, as the prime minister granted the NDP's wish to allow more party members to review top-secret intelligence.
Golden Knights reach 2nd Stanley Cup Final after Game 6 win over Stars
William Karlsson, William Carrier and Jonathan Marchessault are finally getting another chance in the Stanley Cup Final, after the first one that came so quick for the Vegas Golden Knights.
Caleb Martin helps Heat to 103-84 Game 7 win over Celtics and spot in NBA Finals
Eastern Conference finals Most Valuable Player Jimmy Butler scored 28 points, and Caleb Martin had 26 points and 10 rebounds to help the eighth-seeded Miami Heat beat the Celtics 103-84 in Game 7 on Monday night and advance to the NBA Finals for the second time in four seasons.
Canadian parliamentarians condemn Uganda's recently passed anti-homosexuality law
Canadian political leaders and parliamentarians are denouncing a new law passed in Uganda that imposes harsh penalties, including the death penalty, for certain cases involving homosexuality.
Free prescription drugs could reduce overall health-care costs in Canada: study
Overall health-care costs could be reduced in Canada by providing free prescription drugs to patients, according to a new study.
Northern B.C., Alberta and all of Ontario under 'high' to 'extreme' wildfire risk: What to know
There's a heightened risk of wildfires across the country during what has been one of the earliest fire seasons on record. From British Columbia to Nova Scotia, here's where the risk is highest.
Strategic city planning can mitigate 'urban heat island' effect, make cities cooler in summer: study
New research from Penn State University found certain factors can contribute to reducing what’s known as the 'urban heat island' effect, and that climate knowledge can contribute to better city planning and design.